Claims for Patent: 10,919,892

Summary for Patent: 10,919,892

Title:	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Abstract:	Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Inventor(s):	McGee; Kevin (San Diego, CA), Li; Bin-Feng (Suzhou Industrial Park, CN), Branum; Shawn (San Diego, CA)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	16/929,696
Patent Claims:	1. A VMAT2 inhibitor that is (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) having an impurity profile comprising total impurities in an amount that is no greater than about 5% by weight. 2. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises total impurities in an amount that is no greater than about 3% by weight. 3. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises total impurities in an amount that is no greater than about 2.5% by weight. 4. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises total impurities in an amount that is no greater than about 2% by weight. 5. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises total impurities in an amount that is no greater than about 1.5% by weight. 6. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises total impurities in an amount that is no greater than about 1% by weight. 7. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises total impurities in an amount that is no greater than about 0.5% by weight. 8. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises total impurities in an amount that is no greater than about 0.1% by weight. 9. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises one or more impurities chosen from: (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[- 2,1-a]isoquinolin-2-ol or a salt thereof, (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-aminopropanoate, and (S)-(2S,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate. 10. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises (R)-(2R,3R,11bR)-3-isobutyl-9,10,11b-trimethoxy-2,3,4,6,7,11b-h- exahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate. 11. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises 6,7-dimethoxy-3,4-dihydroisoquinoline. 12. The VMAT2 inhibitor of claim 1, wherein the impurity profile comprises (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-7-oxo-2,3,4,6,7,11b-- hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl-2-amino-3-methylbutanoate. 13. The VMAT2 inhibitor of claim 1, having an impurity profile comprising one or more impurities chosen from metal-based impurities. 14. The VMAT2 inhibitor of claim 1, having an impurity profile comprising one or more impurities chosen from dimethylamine, formaldehyde, ethyl chloride, and isopropyl chloride. 15. The VMAT2 inhibitor of claim 1, wherein (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) has a weight loss on drying (LOD) of no greater than about 5% by weight. 16. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 4% by weight. 17. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 3% by weight. 18. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 2% by weight. 19. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 1% by weight. 20. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 0.8% by weight. 21. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 0.6% by weight. 22. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 0.4% by weight. 23. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 0.2% by weight. 24. The VMAT2 inhibitor of claim 15, having a weight loss on drying (LOD) of no greater than about 0.1% by weight. 25. A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 1 and a pharmaceutically acceptable carrier. 26. A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 2 and a pharmaceutically acceptable carrier. 27. A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 9 and a pharmaceutically acceptable carrier. 28. A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 14 and a pharmaceutically acceptable carrier. 29. A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 15 and a pharmaceutically acceptable carrier. 30. A pharmaceutical composition comprising (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) of claim 18 and a pharmaceutically acceptable carrier.